This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giannoni, E.
Right arrow Articles by Bugnon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannoni, E.
Right arrow Articles by Bugnon, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2563-2568, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01149-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Prospective Determination of Plasma Imipenem Concentrations in Critically Ill Children

Eric Giannoni,1 Philippe Moreillon,2* Jacques Cotting,1 Adrien Moessinger,1 Jacques Bille,3 Laurent Décosterd,4 Giorgio Zanetti,5 Paul Majcherczyk,2 and Denis Bugnon6

Department of Pediatrics, CHUV, CH-1011 Lausanne, Switzerland,1 Department of Fundamental Microbiology, University of Lausanne, Biophore Building, CH-1015 Lausanne, Switzerland,2 Institute of Microbiology, CHUV, CH-1011 Lausanne, Switzerland,3 Division of Clinical Pharmacology, CHUV, CH-1011 Lausanne, Switzerland,4 Department of Hospital Hygiene, CHUV, CH-1011 Lausanne, Switzerland,5 Laboratoire d'Antibiologie (UPRES EA-1156), Medicine School, F-44035 Nantes Cedex 01, France6

Received 2 September 2005/ Returned for modification 27 November 2005/ Accepted 12 April 2006

Plasma imipenem concentrations were measured in 19 critically ill children (median age, 0.8 year; range, 0.02 to 12.9 years). Wide interindividual variations (2 to 4x at peak and >10x at trough concentrations) resulted in unpredictable plasma levels in several children. To avoid subtherapeutic drug levels, we recommend treatment with at least 100 mg/kg of body weight/day of imipenem-cilastatin for critically ill children requiring such therapy.

* Corresponding author. Mailing address: Institute of Fundamental Microbiology, University of Lausanne, Biology Building, CH-1015 Lausanne, Switzerland. Phone: 41-21-692 5600. Fax: 41-21-692 5605. E-mail: Philippe.Moreillon{at}unil.ch.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2563-2568, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01149-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lamoth, F., Buclin, T., Pascual, A., Calandra, T., Marchetti, O. (2009). Imipenem underdosing as a cause of persistent neutropenic fever?. J Antimicrob Chemother 64: 665-667 [Full Text]  
  • Jaruratanasirikul, S., Sudsai, T. (2009). Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother 63: 560-563 [Abstract] [Full Text]  
  • Lamoth, F., Buclin, T., Csajka, C., Pascual, A., Calandra, T., Marchetti, O. (2009). Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies. Antimicrob. Agents Chemother. 53: 785-787 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»